Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Calcitonin pre-treatment for Sestamibi SPECT-CT in primary hyperparathyroidism
NCT03935984Phase 4Recruiting
- Start
- May 2019
- Primary completion
- Jun 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of calcitonin salmon in primary hyperparathyroidism (PHPT). Primary endpoint: Sensitivity of SPECT-CT at 1 year. Started May 2019; status: recruiting.
02
Drugs
calcitonin salmon
03
Conditions
primary hyperparathyroidism (PHPT)
Beyond the preview
Go deeper on NCT03935984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03935984.